Serum SP-A and KL-6 Levels Can Predict the Improvement and Deterioration of Patients with Interstitial Pneumonia with Autoimmune Features

Overview

Journal BMC Pulm Med

Publisher Biomed Central

Specialty Pulmonary Medicine

Date 2020 Dec 3

PMID 33267857

Citations 15

Authors

Jingxian Wang

Peiyan Zheng

Zhifeng Huang

Huimin Huang

Mingshan Xue

Chenxi Liao

Baoqing Sun

Nanshan Zhong

Affiliations

Soon will be listed here.

Abstract

Background: Some patients with interstitial pneumonia with autoimmune features (IPAF) showed a progressive course despite therapy. This study aimed to evaluate whether serial changes in the serum levels of surfactant protein-A (SP-A) and Krebs von den Lungen-6 (KL-6) can predict disease progression.

Methods: Sixty-four patients with IPAF and 41 patients with non-fibrotic lung disease (non-FLD) were examined. Based on long-term changes in lung function, 36 IPAF patients who were followed up for more than 3 months were divided into a progressive group (n = 9), an improvement group (n = 13), and a stable group (n = 14). Serum KL-6 and SP-A levels were measured. The sensitivity, specificity, cut-off value, and area under the curve (AUC) value for each of the indices were determined using receiver operating characteristic (ROC) curve analysis. The expression differences in these biomarkers and their correlation with disease severity were analyzed.

Results: Compared with non-FLD patients, serum SP-A and KL-6 levels in IPAF patients were increased significantly [SP-A: (p < 0.001); KL-6: (p < 0.001)] and negatively correlated with DLCO (SP-A: r = - 0.323, p = 0.018; KL-6: r = - 0.348, p = 0.0011). In patients with progressive disease, the posttreatment serum SP-A and KL-6 levels were increased significantly compared with pretreatment levels [SP-A: (p = 0.021); KL-6: (p = 0.008)]. In patients showing improvement, the levels were decreased significantly [SP-A (p = 0.007) and KL-6 (p = 0.002)]. Changes in serum biomarkers (Delta SP-A and Delta KL-6) were significantly negatively correlated with changes in lung function (Delta FVC, Delta DLCO and Delta FEV1) (r = 0.482, p < 0.05). A significant positive correlation was found between Delta SP-A and Delta KL-6 (r = 0.482, p < 0.001).

Conclusions: Serum SP-A and KL-6 offer high sensitivity and specificity for the diagnosis of IPAF. The decrease in serum SP-A and/or KL-6 levels in patients with IPAF is related to the improvement in pulmonary function. SP-A and KL-6 may be important biomarkers for predicting disease progression in patients with IPAF.

Citing Articles

Serum KL-6 and SP-D: Markers of Lung Function in Autoimmune-Related Interstitial Lung Diseases.

Miadlikowska E, Milkowska-Dymanowska J, Bialas A, Makowska J, Lewandowska-Polak A, Pula A Int J Mol Sci. 2025; 26(3).

PMID: 39940859 PMC: 11817276. DOI: 10.3390/ijms26031091.

Controlled human exposures: a review and comparison of the health effects of diesel exhaust and wood smoke.

Long E, Rider C, Carlsten C Part Fibre Toxicol. 2024; 21(1):44.

PMID: 39444041 PMC: 11515699. DOI: 10.1186/s12989-024-00603-8.

CA 15 - 3 in screening for systemic autoimmune rheumatic disease associated interstitial lung disease: a single center cross-sectional study.

Frketic Marovic K, Kardum Z, Sahinovic I, Tolic A, Kasap Basioli E, Patrk J Rheumatol Int. 2024; 44(10):2017-2025.

PMID: 39180532 DOI: 10.1007/s00296-024-05694-2.

The clinical value of KL-6 for predicting the occurrence and severity of connective tissue disease-associated interstitial lung disease is not affected by CTD type or treatment.

Xing H, Liang H PeerJ. 2024; 12:e17792.

PMID: 39131623 PMC: 11317038. DOI: 10.7717/peerj.17792.

The role of biomarkers in the diagnosis and treatment follow-up of idiopathic pulmonary fibrosis.

Kayikci A, Alatas F, Alatas I, Yildirim H, Ozen H Sarcoidosis Vasc Diffuse Lung Dis. 2024; 41(2):e2024015.

PMID: 38940711 PMC: 11275546. DOI: 10.36141/svdld.v41i2.15454.

References

Li Y, Zheng Z, Han Q, Li Z, Xie R, Zhang R . IPAF should receive early treatment for sharing similar clinical characteristics as CTD-ILD: a report from 273 Chinese patients. Clin Rheumatol. 2020; 39(12):3817-3823. DOI: 10.1007/s10067-020-05149-6. View

Greene K, King Jr T, Kuroki Y, Bucher-Bartelson B, Hunninghake G, Newman L . Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J. 2002; 19(3):439-46. DOI: 10.1183/09031936.02.00081102. View

Hu C, Wu C, Yang E, Huang H, Xu D, Hou Y . Serum KL-6 is associated with the severity of interstitial lung disease in Chinese patients with polymyositis and dermatomyositis. Clin Rheumatol. 2019; 38(8):2181-2187. DOI: 10.1007/s10067-019-04501-9. View

Lee J, Lee E, Ha Y, Kang E, Lee Y, Song Y . Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease. Arthritis Res Ther. 2019; 21(1):58. PMC: 6376648. DOI: 10.1186/s13075-019-1835-9. View

Derrien M, van Passel M, van de Bovenkamp J, Schipper R, de Vos W, Dekker J . Mucin-bacterial interactions in the human oral cavity and digestive tract. Gut Microbes. 2011; 1(4):254-268. PMC: 3023607. DOI: 10.4161/gmic.1.4.12778. View

Konno S, Shigemura M, Ogi T, Shimizu K, Suzuki M, Kaga K . Clinical Course of Histologically Proven Multifocal Micronodular Pneumocyte Hyperplasia in Tuberous Sclerosis Complex: A Case Series and Comparison with Lymphangiomyomatosis. Respiration. 2018; 95(5):310-316. DOI: 10.1159/000486101. View

Sebastiani M, Cassone G, De Pasquale L, Cerri S, Casa G, Vacchi C . Interstitial pneumonia with autoimmune features: A single center prospective follow-up study. Autoimmun Rev. 2019; 19(2):102451. DOI: 10.1016/j.autrev.2019.102451. View

Hamai K, Iwamoto H, Ishikawa N, Horimasu Y, Masuda T, Miyamoto S . Comparative Study of Circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as Disease Markers of Idiopathic Pulmonary Fibrosis. Dis Markers. 2016; 2016:4759040. PMC: 4886062. DOI: 10.1155/2016/4759040. View

Schicke E, Cseresnyes Z, Rennert K, Vau V, Haupt K, Hornung F . Lung Infection Results in Down-Regulation of Surfactant Protein-A Mainly Caused by Pro-Inflammatory Macrophages. Microorganisms. 2020; 8(4). PMC: 7232181. DOI: 10.3390/microorganisms8040577. View

10.

Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M . New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest. 1989; 96(1):68-73. DOI: 10.1378/chest.96.1.68. View

11.

Arai S, Kurasawa K, Maezawa R, Owada T, Okada H, Fukuda T . Marked increase in serum KL-6 and surfactant protein D levels during the first 4 weeks after treatment predicts poor prognosis in patients with active interstitial pneumonia associated with polymyositis/dermatomyositis. Mod Rheumatol. 2012; 23(5):872-83. DOI: 10.1007/s10165-012-0756-0. View

12.

Ishikawa N, Hattori N, Yokoyama A, Kohno N . Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir Investig. 2012; 50(1):3-13. DOI: 10.1016/j.resinv.2012.02.001. View

13.

Collard H, King Jr T, Bucher Bartelson B, Vourlekis J, Schwarz M, Brown K . Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003; 168(5):538-42. DOI: 10.1164/rccm.200211-1311OC. View

14.

Sokai A, Tanizawa K, Handa T, Kanatani K, Kubo T, Ikezoe K . Importance of serial changes in biomarkers in idiopathic pulmonary fibrosis. ERJ Open Res. 2017; 3(3). PMC: 5576222. DOI: 10.1183/23120541.00019-2016. View

15.

Song J, Do K, Jang S, Colby T, Han S, Kim D . Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis. Chest. 2013; 143(5):1422-1429. DOI: 10.1378/chest.11-2735. View

16.

Cottin V, Wollin L, Fischer A, Quaresma M, Stowasser S, Harari S . Fibrosing interstitial lung diseases: knowns and unknowns. Eur Respir Rev. 2019; 28(151). PMC: 9489101. DOI: 10.1183/16000617.0100-2018. View

17.

Bonella F, Volpe A, Caramaschi P, Nava C, Ferrari P, Schenk K . Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement. Sarcoidosis Vasc Diffuse Lung Dis. 2011; 28(1):27-33. View

18.

Cottin V, Hansell D, Sverzellati N, Weycker D, Antoniou K, Atwood M . Effect of Emphysema Extent on Serial Lung Function in Patients with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2017; 196(9):1162-1171. DOI: 10.1164/rccm.201612-2492OC. View

19.

Yamakawa H, Hagiwara E, Ikeda S, Iwasawa T, Otoshi R, Tabata E . Evaluation of changes in the serum levels of Krebs von den Lungen-6 and surfactant protein-D over time as important biomarkers in idiopathic fibrotic nonspecific interstitial pneumonia. Respir Investig. 2019; 57(5):422-429. DOI: 10.1016/j.resinv.2019.03.006. View

20.

Yoshikawa T, Otsuka M, Chiba H, Ikeda K, Mori Y, Umeda Y . Correction to: Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis. BMC Pulm Med. 2020; 20(1):131. PMC: 7206697. DOI: 10.1186/s12890-020-1118-x. View